Navigation Links
Genesis Pharmaceuticals Changes Auditors

LAIYANG, China, March 11 /Xinhua-PRNewswire-FirstCall/ -- Genesis Pharmaceuticals Enterprises, Inc. (OTC Bulletin Board: GTEC) ("Genesis" or the "Company"), a pharmaceutical company with its principal operations in the People's Republic of China, announced that it changed auditors from Sherb & Co., LLP to Moore Stephens Wurth Frazer & Torbet, LLP.

The client-auditor relationship between Genesis Pharmaceuticals Enterprises, Inc. and Sherb & Co., LLP ended as of February 25, 2008 in regard to all accounting and auditing services, and all quarterly reporting up through and including February 25, 2008. All accounting and auditing services and all quarterly reports from February 25, 2008 on will be handled by Moore Stephens Wurth Frazer & Torbet, LLP. Sherb & Co., LLP, were Genesis' auditors for the fiscal years ended September 30, 2007 and September 30, 2006. There were no disagreements between Genesis Pharmaceuticals Enterprises, Inc. and Sherb & Co., LLP.

"We look forward to working with Moore Stephens and continuing to provide the investment community with timely and accurate financial information that reflects Genesis' activities," said Mr. Cao Wubo, Chairman and CEO of Genesis Pharmaceuticals Enterprises, Inc.

About Genesis Pharmaceuticals Enterprises

Genesis Pharmaceuticals Enterprises, Inc. is a U.S. public company engaged through its controlled affiliates in the research, development, production, marketing and sales of pharmaceutical products in the People's Republic of China. Its operations are located in Northeast China in an Economic Development Zone in Laiyang City, Shandong province. Genesis is a major pharmaceutical company in China producing both western and Chinese herbal- based medical drugs in tablet, capsule and granule form. The Company maintains a representative office in the U.S. For more information, refer to .

Safe Harbor Statement

Certain statements set forth in this press release constitute "forward- looking statements." Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the Company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to introduce, manufacture and distribute new drugs. Actual results may differ materially from predicted results, and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's ability to obtain raw materials needed in manufacturing, the continuing employment of key employees, the failure risks inherent in testing any new drug, the possibility that regulatory approvals may be delayed or become unavailable, patent or licensing concerns that may include litigation, direct competition from other manufacturers and product obsolescence. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.

For more information, please contact:

Genesis Pharmaceuticals Enterprises, Inc.

Ms. Elsa Sung CFO

Tel: +1-877-895-3650 x701


CCG Elite Investor Relations, Inc.

Mr. Crocker Coulson, President

Tel: +1-646-213-1915 (New York)


SOURCE Genesis Pharmaceuticals Enterprises, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Cardiogenesis Corporation Announces Rescheduled Fourth Quarter and Full Year 2007 Earnings Release
2. Cardiogenesis Corporation Reports Delay in Earnings Release and Conference Call
3. Cardiogenesis Corporation to Report 2007 Fourth Quarter and Year-End Results on March 4th
4. Thermogenesis Announces New Initiative to Address Veterinary Regenerative Medicine
5. Childrens Hospital Boston Mourns the Death of Dr. Judah Folkman, World Renowned Researcher and Founder of the Field of Angiogenesis
6. Genesis Pharmaceuticals Announces Results for The First Quarter of Fiscal Year 2008
7. Cardiogenesis Receives FDA Approval for PEARL 5.0 Robotic Hand Piece
8. ThermoGenesis Corp. Reports First Quarter 2008 Results
9. Tissue Genesis Signs Exclusive Distribution and License Agreement with SpineSmith
10. Researchers chart the genetic mechanisms behind the genesis of fat cells
11. Genesis Technology Group Retains CCG Elite
Post Your Comments:
(Date:6/26/2016)... ... 27, 2016 , ... Quality metrics are proliferating in cancer care, and are ... the eye of the beholder, according to experts who offered insights and commentary in ... Managed Care. For the full issue, click here . , For the American ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are ... with endometriosis. These women need a treatment plan to not only alleviate symptoms ... can help for preservation of fertility and ultimately achieving a pregnancy. The specialists ...
(Date:6/25/2016)... , ... June 25, 2016 , ... First Choice ... States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm ... Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... A ... procedures that most people are unfamiliar with. The article goes on to state that ... but also many of these less common operations such as calf and cheek reduction. ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Global law ... magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition are ... , Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016   Bay Area ... Network,s Dean Center for Tick Borne Illness ... and Rehabilitation, MIT Hacking Medicine, University of California, ... today announced the five finalists of Lyme ... disease.  More than 100 scientists, clinicians, researchers, entrepreneurs, ...
(Date:6/24/2016)... The Academy of Managed Care Pharmacy (AMCP) ... would allow biopharmaceutical companies to more easily share health ... and coverage decisions, a move that addresses the growing ... The recommendations address restrictions in the sharing of ... label, a prohibition that hinders decision makers from accessing ...
(Date:6/24/2016)... Research and Markets has announced the addition of ... report to their offering. ... The World Market for Companion Diagnostics covers the world market ... the report includes the following: , World ... Region (N. America, EU, ROW), 2015-2020 , World IVD ...
Breaking Medicine Technology: